Graf Akcie IDXG (Interpace Biosciences Inc). Diskuze k akciím IDXG. Aktuální informace IDXG.

Základní informace o společnosti Interpace Biosciences Inc (Akcie IDXG)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 35.58M
Hodnota podniku (EV) 36.4M
Tržby 38.882M
EBITDA -23.91
Zisk -22.03
Růst v tržbách Q/Q 104.83 %
Růst v tržbách Y/Y 47.03 %
P/E (Cena vůči ziskům) N/A
Forward P/E 0.27
EV/Sales 0.94
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales 0.90
P/FCF N/A
Price/Book -1.20
Účetní hodnota na akcii -7.20
Hotovost na akcii 0.83
FCF vůči ceně -42.34 %
Počet zaměstnanců 152
Tržba na zaměstnance 255.803k
Profit margin -81.64 %
Operating margin -54.40 %
Gross margin 33.10 %
EBIT margin -55.12 %
EBITDA margin -61.49 %
EPS - Zisk na akcii N/A
EPS - Kvartální růst -33.82 %
EPS - Očekávaný růst příští rok -59.74 %
Return on assets -48.04 %
Return on equity 73.70 %
ROIC -123.02 %
ROCE -105.21 %
Dluhy/Equity -0.97
Čistý dluh/EBITDA -0.43
Current ratio 0.64
Quick Ratio 0.64
Volatilita 4.89
Beta 0.00
RSI 47.77
Cílová cena analytiků 11
Známka akcie (dle analytiků) 1.00
Insider ownership 26.70 %
Institutional ownership 0.32 %
Počet akcií 4.161M
Procento shortovaných akcií 1.18 %
Short ratio 0.19 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 1998
Země United States

Finanční výsledky akcie IDXG

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$24.22$21.896$15.897$13.085$9.432$1.474
Cost Of Goods Sold$15.888$10.197$7.358$6.641$6.91$1.268
Gross Profit$8.332$11.699$8.539$6.444$2.522$0.206
Research And Development Expenses$2.81$2.124$1.461$1.647$2.292$0.255
SG&A Expenses$25.479$17.097$15.72$15.966$27.28$14.918
Other Operating Income Or Expenses$-2.49$-1.522$5.602$8.497$6.12$-2.086
Operating Expenses$50.656$34.529$22.19$19.527$49.84$19.3
Operating Income$-26.436$-12.633$-6.293$-6.442$-40.408$-17.826
Total Non-Operating Income/Expense$-0.244$-0.068$-6.839$-2.13$-3.798$-0.67
Pre-Tax Income$-26.68$-12.701$-13.132$-8.572$-44.206$-18.496
Income Taxes$-0.028$0.018$-0.395$-0.162$-13.136$-5.03
Income After Taxes$-26.652$-12.719$-12.737$-8.41$-31.07$-13.466
Other Income------
Income From Continuous Operations$-26.652$-12.719$-12.737$-8.41$-31.07$-13.466
Income From Discontinued Operations$-0.088$0.016$0.521$0.078$19.714$-2.607
Net Income$-27.169$-12.703$-12.216$-8.332$-11.356$-16.073
EBITDA$-21.912$-8.832$-2.486$-1.959$-19.712$-15.435
EBIT$-26.436$-12.633$-6.293$-6.442$-40.408$-17.826
Basic Shares Outstanding432000
Shares Outstanding432000
Basic EPS$-7.25$-4.52$-7.70$-45.90$-73.40$-108.00
EPS - Earnings Per Share$-7.25$-4.52$-7.70$-45.90$-73.40$-108.00
# 2020 2019 2018 2017 2016 2015
Current Ratio0.95482.04422.44820.26110.821.3362
Long-term Debt / Capital-2.0284--0.54770.35680.5744
Debt/Equity Ratio-0.6698--1.21080.6441.3495
Gross Margin34.401353.429953.714549.247226.738813.9756
Operating Margin-109.1495-57.6955-39.5861-49.2319-428.4139-1209.362
EBIT Margin-109.1495-57.6955-39.5861-49.2319-428.4139-1209.362
EBITDA Margin-90.4707-40.3361-15.6382-14.9713-208.9907-1047.151
Pre-Tax Profit Margin-110.1569-58.006-82.6068-65.5101-468.6811-1254.817
Net Profit Margin-112.1759-58.0152-76.8447-63.676-120.3986-1090.434
Asset Turnover0.46990.70340.29660.31320.13930.0127
Inventory Turnover Ratio------
Receiveable Turnover2.34282.3094.62535.92353.36140.3843
Days Sales In Receivables155.7956158.078978.914661.619108.5867949.8915
ROE - Return On Equity595.0462-82.3449-31.9471-128.7704-238.3034-66.9218
Return On Tangible Equity92.6672-437.3795-188.305728.1959102.022731.5164
ROA - Return On Assets-51.7113-40.8616-23.764-20.1302-45.8855-11.618
ROI - Return On Investment1802.028-82.3449-31.9471-58.245-153.2731-28.4838
Book Value Per Share-1.14235.383814.322830.013873.8279130.9941
Operating Cash Flow Per Share-1.98076.601132.207886.2895-18.2662-86.0502
Free Cash Flow Per Share-1.85286.460132.189488.5698-1.4136-92.8308